The partnership will use F-star’s platforms for developing immunotherapies for cancer patients. Credit: National Cancer Institute on Unsplash.

invoX subsidiary F-star Therapeutics has signed a strategic discovery partnership and licence deal with Takeda to develop multi-specific antibodies.

The partnership will use F-star’s fully-human Fcab and tetravalent mAb² platforms to analyse and develop immunotherapies for cancer.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The companies will work on the development of as-yet-undisclosed new Fcab domains against immuno-oncology targets. 

Takeda will obtain an exclusive global royalty-bearing licence to carry out research, development and marketing of the antibodies containing Fcab domains that will result from the partnership.

The rights for researching, developing and marketing antibodies with other Fcab domains will be retained by F-star. 

See Also:

F-star is eligible to receive an undisclosed upfront payment and investment for research during the partnership period.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Takeda will make contingent payments of $1bn to F-star on meeting development and marketing milestones. 

F-star will also receive royalty payments on net yearly sales of any product arising from the licence.

F-star Therapeutics head and chief scientific officer Neil Brewis stated: “We are delighted to expand our relationship with Takeda which shares our vision of developing pioneering multi-specific immunotherapies so more people with cancer can live longer with improved lives. 

“This strategic collaboration leverages the capabilities of both companies by combining F-star’s clinically validated Fcab and mAb² platforms with Takeda’s unique understanding of the immune system and its ability to progress drugs to the clinic.”

In May 2023, Takeda and KSQ Therapeutics extended their immuno-oncology collaboration for novel tumour-intrinsic targets.